JW (Cayman) Therapeutics CoJWCTF 28 PB Ratio is 1.25 as of Jul. 01, 2026, which is 123% above its 10-year median of 0.56. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, JW (Cayman) Therapeutics Co ranks better than 80.88% on this metric.
The historical rank and industry rank for JW (Cayman) Therapeutics Co's PB Ratio or its related term are showing as below:
JWCTF'
s PB Ratio Range Over the Past 10 Years
Min: 0.28 Med: 0.56 Max: 1.98
Current: 1.02
During the past 8 years, JW (Cayman) Therapeutics Co's highest PB Ratio was 1.98. The lowest was 0.28. And the median was 0.56.
JWCTF's PB Ratio is ranked better than 80.88% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs JWCTF: 1.02
During the past 12 months, JW (Cayman) Therapeutics Co's average Book Value Per Share Growth Rate was -50.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -31.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of JW (Cayman) Therapeutics Co was -24.80% per year. The lowest was -38.70% per year. And the median was -29.00% per year.
Back to Basics: PB Ratio
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
JW (Cayman) Therapeutics Co PB Ratio Related Terms
JW (Cayman) Therapeutics Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
JW (Cayman) Therapeutics Co (JWCTF) has a PB Ratio of 1.25 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on JW (Cayman) Therapeutics Co and its competitors. This is 123% above median its historical median of 0.56. Over the past decade, JW (Cayman) Therapeutics Co's PB Ratio has ranged from 0.28 to 1.98. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #235 out of 1229 companies in the Biotechnology industry, placing it in the top 19.1%.
Is JW (Cayman) Therapeutics Co's PB Ratio too high?
JW (Cayman) Therapeutics Co's current PB Ratio of 1.25 is 123% above median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 1.98. The Biotechnology industry median PB Ratio is 2.87. JW (Cayman) Therapeutics Co's value of 1.25 is 56.4% below this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #235 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #235 out of 1229 companies for PB Ratio. This places JW (Cayman) Therapeutics Co in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.87. JW (Cayman) Therapeutics Co's value of 1.25 is 56.4% below this benchmark. Historically, JW (Cayman) Therapeutics Co's own PB Ratio has ranged from 0.28 to 1.98 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 2.87, JW (Cayman) Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current PB Ratio of 1.25 is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current PB Ratio is 1.25, which is 123% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current PB Ratio is 1.25, which is 123% above median its 10-year median of 0.56 and 56.4% below the Biotechnology industry median of 2.87. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current PB Ratio is 1.25 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
PB Ratio: 1.25 (123% above median its 10-year median of 0.56)
GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
Industry Position: 56.4% below the Biotechnology median (#235 of 1229)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score
Get the complete analysis for JWCTF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
